฿0
+฿0(0.00%)
No data
data.updated
v2.stock.overview v2.daily.trading v2.range.52w
key.stats
yesterday.close฿8
market.size฿1.31B
volume.trade2.58M
pe.ratio2.47
div.yield0.00%
diluted.eps2.71
net.income฿440.30M
revenue฿1.12B
earnings.date2026-05-14
eps.estimate0.25
rev.estimate฿78.32M
shares.out159.96M
beta2.648
about.stock
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
sectorHealthcare
industryBiotechnology
ceoJohn Charles Jacobs
headquartersGaithersburg,MD,US
websitehttps://www.novavax.com
employees749.00
avg.revenue฿1.49M
income.per.emp฿587.85K
stock.faq
stock.price
x
current.stats
52w.range.q
x
pe.ratio.q
x
market.cap.q
x
eps.recent.q
x
buy.sell.q
x
price.factors
x
buy.how
x
risk.warn
risk.notice
disclaimer2
risk.disclosure
